Hotte SJ - Search Results

1

Management algorithms for metastatic prostate cancer.

Malone S, Shayegan B, Basappa NS, Chi K, Conter HJ, Hamilton RJ, Hotte SJ, Saad F, So AI, Park-Wyllie L, Hew H, McLeod D, Gotto G. Malone S, et al. Among authors: hotte sj. Can Urol Assoc J. 2020 Feb;14(2):50-60. doi: 10.5489/cuaj.5840. Can Urol Assoc J. 2020. PMID: 31039111 Free PMC article. Review.

2

A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer.

Chi KN, Ellard SL, Hotte SJ, Czaykowski P, Moore M, Ruether JD, Schell AJ, Taylor S, Hansen C, Gauthier I, Walsh W, Seymour L. Chi KN, et al. Among authors: hotte sj. Ann Oncol. 2008 Apr;19(4):746-51. doi: 10.1093/annonc/mdm554. Epub 2007 Dec 3. Ann Oncol. 2008. PMID: 18056648 Free article. Clinical Trial.

3

A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer.

Chi KN, Siu LL, Hirte H, Hotte SJ, Knox J, Kollmansberger C, Gleave M, Guns E, Powers J, Walsh W, Tu D, Eisenhauer E. Chi KN, et al. Among authors: hotte sj. Clin Cancer Res. 2008 Feb 1;14(3):833-9. doi: 10.1158/1078-0432.CCR-07-1310. Clin Cancer Res. 2008. PMID: 18245546 Clinical Trial.

4

Interleukin-2 in the treatment of unresectable or metastatic renal cell cancer: a systematic review and practice guideline.

Hotte S, Waldron T, Canil C, Winquist E. Hotte S, et al. Can Urol Assoc J. 2007 Mar;1(1):27-38. doi: 10.5489/cuaj.34. Can Urol Assoc J. 2007. PMID: 18542758 Free PMC article.

5

Current status of cytokine therapy in management of patients with metastatic renal cell carcinoma.

Kapoor AK, Hotte SJ. Kapoor AK, et al. Among authors: hotte sj. Can Urol Assoc J. 2007 Jun;1(2 Suppl):S28-33. doi: 10.5489/cuaj.65. Can Urol Assoc J. 2007. PMID: 18542782 Free PMC article.

6

Interferon-alfa in the treatment of patients with inoperable locally advanced or metastatic renal cell carcinoma: a systematic review.

Canil C, Hotte S, Mayhew LA, Waldron TS, Winquist E. Canil C, et al. Can Urol Assoc J. 2010 Jun;4(3):201-8. doi: 10.5489/cuaj.853. Can Urol Assoc J. 2010. PMID: 20514286 Free PMC article.

7

A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer.

Sridhar SS, Canil CM, Chi KN, Hotte SJ, Ernst S, Wang L, Chen EX, Juhasz A, Yen Y, Murray P, Zwiebel JA, Moore MJ. Sridhar SS, et al. Among authors: hotte sj. Cancer Chemother Pharmacol. 2011 Apr;67(4):927-33. doi: 10.1007/s00280-010-1389-7. Epub 2010 Jul 3. Cancer Chemother Pharmacol. 2011. PMID: 20602233 Clinical Trial.

8

Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.

Chi KN, Hotte SJ, Yu EY, Tu D, Eigl BJ, Tannock I, Saad F, North S, Powers J, Gleave ME, Eisenhauer EA. Chi KN, et al. Among authors: hotte sj. J Clin Oncol. 2010 Sep 20;28(27):4247-54. doi: 10.1200/JCO.2009.26.8771. Epub 2010 Aug 23. J Clin Oncol. 2010. PMID: 20733135 Clinical Trial.

9

Current management of castrate-resistant prostate cancer.

Hotte SJ, Saad F. Hotte SJ, et al. Curr Oncol. 2010 Sep;17 Suppl 2(Suppl 2):S72-9. doi: 10.3747/co.v17i0.718. Curr Oncol. 2010. PMID: 20882137 Free PMC article.

10

Guidelines for the management of castrate-resistant prostate cancer.

Saad F, Hotte SJ. Saad F, et al. Among authors: hotte sj. Can Urol Assoc J. 2010 Dec;4(6):380-4. doi: 10.5489/cuaj.10167. Can Urol Assoc J. 2010. PMID: 21191494 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

168 results

Search Page